Patents by Inventor Taosheng Chen
Taosheng Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11883491Abstract: Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.Type: GrantFiled: April 30, 2018Date of Patent: January 30, 2024Assignee: St. Jude Children's Research Hospital, Inc.Inventors: Jian Zuo, Fei Zheng, Tetsuji Yamashita, Zoe Kellard, Tal Teitz, Jaeki Min, Taosheng Chen
-
Publication number: 20240002458Abstract: The present disclosure relates to compositions and methods for use in modulating von Hippel-Lindau protein (pVHL) and in identifying pVHL ligands, which can be useful in, for example, treating anti-chronic anemia and anti-chronic ischemia, and also as proteolysis targeting chimeras (PROTACS) to degrade proteins for various therapeutic applications. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: November 8, 2021Publication date: January 4, 2024Inventors: Taosheng Chen, Wenwei Lin, Yongtao Li
-
Patent number: 11446308Abstract: In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: December 9, 2019Date of Patent: September 20, 2022Inventors: Jian Zuo, Tai Teitz, Jie Fang, Asli Goktug, Taosheng Chen, Jaeki Min, R. Kiplin Guy
-
Publication number: 20220091120Abstract: A method of identifying a lead or candidate compound that modulates the activity of GTPase-Activating Protein SH3 Domain-Binding Proteins (G3BP) is provided, which includes determining whether a compound modulates the interaction between the N-terminal Nuclear Transport Factor 2-like (NTF2L) domain of G3BP and FGDF peptide of ubiquitin specific protease 10 (USP10) or non-structural protein 3 (nsP3).Type: ApplicationFiled: December 3, 2021Publication date: March 24, 2022Inventors: J. Paul TAYLOR, Peiguo YANG, Wenwei LIN, Taosheng CHEN
-
Patent number: 11237168Abstract: A method of identifying a lead or candidate compound that modulates the activity of GTPase-Activating Protein SH3 Domain-Binding Proteins (G3BP) is provided, which includes determining whether a compound modulates the interaction between the N-terminal Nuclear Transport Factor 2-like (NTF2L) domain of G3BP and FGDF peptide of ubiquitin specific protease 10 (USP10) or non-structural protein 3 (nsP3).Type: GrantFiled: June 26, 2019Date of Patent: February 1, 2022Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: J. Paul Taylor, Peiguo Yang, Wenwei Lin, Taosheng Chen
-
Patent number: 10947203Abstract: In an aspect, the invention relates to 1,4,5-substituted 1,2,3-triazole and 1,2,4,5-substituted imidazoles having a structure represented by a formula: which are modulators the pregnane X receptor (“PXR”); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of modulating an adverse drug reaction in a mammal using the compounds and pharmaceutical compositions; methods of treatment of a disorder of uncontrolled cellular proliferation, such as a cancer, using the compounds and pharmaceutical compositions; methods of modulating pregnane X receptor activity in a mammal using the compounds and pharmaceutical compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: November 8, 2019Date of Patent: March 16, 2021Assignee: ST. JUDE CHILDREN'S RSEARCH HOSPITALInventors: Taosheng Chen, Wenwei Lin, Yueming Wang
-
Publication number: 20200408759Abstract: A method of identifying a lead or candidate compound that modulates the activity of GTPase-Activating Protein SH3 Domain-Binding Proteins (G3BP) is provided, which includes determining whether a compound modulates the interaction between the N-terminal Nuclear Transport Factor 2-like (NTF2L) domain of G3BP and FGDF peptide of ubiquitin specific protease 10 (USP10) or non-structural protein 3 (nsP3).Type: ApplicationFiled: June 26, 2019Publication date: December 31, 2020Applicant: St. Jude Children's Research HospitalInventors: J. Paul TAYLOR, Peiguo YANG, Wenwei LIN, Taosheng CHEN
-
Publication number: 20200179397Abstract: In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: December 9, 2019Publication date: June 11, 2020Inventors: Jian Zuo, Tal Teitz, Jie Fang, Asli Goktug, Taosheng Chen, Jaeki Min, R. Kiplin Guy
-
Publication number: 20200093923Abstract: Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.Type: ApplicationFiled: April 30, 2018Publication date: March 26, 2020Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITALEINDHOVENInventors: Jian Zuo, Fei Zheng, Tetsuji Yamashita, Zoe Kellard, Tal Teitz, Jaeki Min, Taosheng Chen
-
Publication number: 20200071281Abstract: In an aspect, the invention relates to 1,4,5-substituted 1,2,3-triazole and 1,2,4,5-substituted imidazoles, which are modulators the pregnane X receptor (“PXR”); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of modulating an adverse drug reaction in a mammal using the compounds and pharmaceutical compositions; methods of treatment of a disorder of uncontrolled cellular proliferation, such as a cancer, using the compounds and pharmaceutical compositions; methods of modulating pregnane X receptor activity in a mammal using the compounds and pharmaceutical compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: November 8, 2019Publication date: March 5, 2020Inventors: Taosheng Chen, Wenwei Lin, Yueming Wang
-
Patent number: 10550091Abstract: In an aspect, the invention relates to 1,4,5-substituted 1,2,3-triazole and 1,2,4,5-substituted imidazoles, which are modulators the pregnane X receptor (“PXR”); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of modulating an adverse drug reaction in a mammal using the compounds and pharmaceutical compositions; methods of treatment of a disorder of uncontrolled cellular proliferation, such as a cancer, using the compounds and pharmaceutical compositions; methods of modulating pregnane X receptor activity in a mammal using the compounds and pharmaceutical compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: March 10, 2017Date of Patent: February 4, 2020Assignee: St. Jude Children's Research HospitalInventors: Taosheng Chen, Wenwei Lin, Yueming Wang
-
Publication number: 20190077770Abstract: In an aspect, the invention relates to 1,4,5-substituted 1,2,3-triazole and 1,2,4,5-substituted imidazoles, which are modulators the pregnane X receptor (“PXR”); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of modulating an adverse drug reaction in a mammal using the compounds and pharmaceutical compositions; methods of treatment of a disorder of uncontrolled cellular proliferation, such as a cancer, using the compounds and pharmaceutical compositions; methods of modulating pregnane X receptor activity in a mammal using the compounds and pharmaceutical compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: March 10, 2017Publication date: March 14, 2019Inventors: Taosheng CHEN, Wenwei Lin, Yueming Wang
-
Publication number: 20180161340Abstract: In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: June 20, 2016Publication date: June 14, 2018Inventors: Jian Zuo, Tai Teitz, Jie Fang, Asli Goktug, Taosheng Chen, Jaeki Min, R. Kiplin Guy
-
Patent number: 9908890Abstract: The compounds of the invention are antagonists of CAR, with specificity for CAR over other proteins including PXR. The disclosed compounds are useful in treating or controlling cell proliferative disorders, in particular oncological disorders, such as cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: October 16, 2015Date of Patent: March 6, 2018Assignee: St. Jude Children's Research HospitalInventors: Taosheng Chen, Milu Cherian, Wenwei Lin
-
Publication number: 20170226115Abstract: The compounds of the invention are antagonists of CAR, with specificity for CAR over other proteins including PXR. The disclosed compounds are useful in treating or controlling cell proliferative disorders, in particular oncological disorders, such as cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: October 16, 2015Publication date: August 10, 2017Inventors: Taosheng CHEN, Milu Cherian, Wenwei Lin
-
Publication number: 20170189477Abstract: In one aspect, the invention relates to pharmaceutical compositions comprising agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof and agents that inhibit the expression of p27Kip1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof, which are useful for inducing the formation of cochlear hair cells; and methods of treating hearing impairments or disorders using the compositions. In one aspect, the invention relates to pharmaceutical compositions comprising ?-catenin; and agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: December 29, 2016Publication date: July 6, 2017Inventors: Jian Zuo, Taosheng Chen, Brandon Walters, Bryan Kuo, Bradley Walters
-
Patent number: 9572815Abstract: In one aspect, the invention relates to pharmaceutical compositions comprising agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof; and agents that inhibit the expression of p27Kip1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof, which are useful for inducing the formation of cochlear hair cells; and methods of treating hearing impairments or disorders using the compositions. In one aspect, the invention relates to pharmaceutical compositions comprising ?-catenin; and agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: March 15, 2014Date of Patent: February 21, 2017Assignee: St. Jude Children's Research HospitalInventors: Jian Zuo, Taosheng Chen, Brandon Walters, Bryan Kuo, Bradley Walters
-
Publication number: 20160030445Abstract: In one aspect, the invention relates to pharmaceutical compositions comprising agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof; and agents that inhibit the expression of p27Kip1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof, which are useful for inducing the formation of cochlear hair cells; and methods of treating hearing impairments or disorders using the compositions. In one aspect, the invention relates to pharmaceutical compositions comprising ?-catenin; and agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: March 15, 2014Publication date: February 4, 2016Applicant: St. Jude Children's Research HospitalInventors: Jian Zuo, Taosheng Chen, Brandon Walters, Bryan Kuo, Bradley Walters
-
Publication number: 20160033531Abstract: In one aspect, the invention relates to compounds useful as fluorescence assay probes, methods of making same, and methods of using same to assay ligand binding interactions with PXR. In various aspects, the invention pertains to compositions comprising a polypeptide comprising a pregnane X receptor polypeptide, or a ligand binding fragment polypeptide thereof; and a molecule comprising a BODIPY residue and a vinca alkaloid residue. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: March 15, 2014Publication date: February 4, 2016Inventors: Taosheng Chen, Wenwei Lin